Hybio Pharmaceutical (SHE:300199) received approval from Indonesia's drug and food regulatory for the marketing of carbetocin injection, which trades as Uterocin, according to a Shenzhen bourse filing on Friday.
The drug is used to reduce the risk of postpartum hemorrhage.
The pharmaceutical company's shares jumped by less than 4% at the close.
